MedTrace Logo

Pulse Shortwave Therapy in Cervical Osteoarthritis

NCT03542955 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-08-30

No results posted yet for this study

Summary

The ActiPatch is an FDA cleared pain therapy device that uses pulsed shortwaves to interrupt pain signals at the nerve. 200 patients will be randomized and divided into an ActiPatch treatment group and comparison analgesic drug therapy group . Subjects will be assessed with the Neck Disability Index (NDI) at baseline and at four weeks and VAS scores will be recorded in order to determine the efficacy of the ActiPatch device compared to Etoricoxib. Cervical osteoarthritis causes chronic neck pain which could potentially be alleviated by the ActiPatch without the use of medication.

Conditions

  • Cervical Osteoarthritis

Interventions

DEVICE

ActiPatch

A Pulsed Shortwave Therapy Device

DRUG

Etoricoxib 60 mg

nonsteroidal anti-inflammatory drug used as standard therapy

Sponsors & Collaborators

  • BioElectronics Corporation

    lead INDUSTRY

Principal Investigators

  • Rachid Mohammad, MD · New Mazloum Hospital

  • Omar Tabbouche, Pharm D · New Mazloum Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-07-30
Completion
2019-07-30
FDA Device
Yes

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542955 on ClinicalTrials.gov